Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 40Active not recruiting 13Recruiting 12Unknown 9Terminated 7Withdrawn 3Not yet recruiting 2Enrolling by invitation 2

Sponsor Class

OTHER_GOV 1OTHER 1NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 12CNS 5Breast 3Sarcoma 2Thoracic 1Head & Neck 1Dermatologic 1

Conditions

Breast Neoplasms 3

Interventions

Paclitaxel 31Cyclophosphamide 25Trastuzumab 23Doxorubicin 17Docetaxel 15Carboplatin 15pembrolizumab 13Radiotherapy 11Letrozole 11Capecitabine 11exemestane 10Fulvestrant 10Magnetic Resonance Spectroscopy 8Lapatinib 8Biopsy 8eribulin 7abemaciclib 7Taxes 7Bevacizumab 7Anastrozole 7pertuzumab 6palbociclib 6Neoadjuvant Therapy 6Goserelin 6Drug Therapy 6Aromatase Inhibitors 6130-nm albumin-bound paclitaxel 6Therapeutics 5Saline Solution 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Surgical Procedures, Operative × Breast × Clear all
NCT00855114 2017-12-02

Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery

Masonic Cancer Center, University of Minnesota

Phase 2 Withdrawn
Breast

Breast Neoplasms

NCT01906112 2015-02-27

Role of Surgery for the Primary in Patients With Breast Cancer Stage IV.

National Cancer Institute, Thailand

Phase 3 Withdrawn
Breast

Breast Neoplasms

NCT00080613 2013-07-10

Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer

National Cancer Institute (NCI)

Phase 2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡